ChitogenX

ChitogenX Inc. is dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing. Headquartered in Kickland, Quebec, the company, formerly known as Ortho Regenerative Technologies Inc., focuses on clinical stage regenerative medicine. Their proprietary RESTORE technology platform utilizes a muco-adhesive CHITOSAN based biopolymer matrix to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC) to enhance healing in musculoskeletal conditions. The company's lead product, ORTHO-R, a Chitosan-PRP hybrid biologic implant combination, aims to increase the healing rates of occupational and sports-related injuries to tendons, ligaments, and cartilage such as the meniscus. Currently undergoing a U.S. Phase I/II clinical trial for rotator cuff tear repair, this product is attracting interest from the medical community. ChitogenX is also developing other formulations to leverage the technology’s characteristics for various tissues damaged by trauma or disease. Founded in 2015, ChitogenX operates within the Biotechnology and Health Care industries. Their last investment, a $2.50M Post-IPO Equity investment, took place on April 4, 2023. The investors involved in this latest funding round are not disclosed. For more detailed information about ChitogenX, one can visit the company's website at www.chitogenx.com and find additional resources on SEDAR at www.sedar.com.